{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:10:01Z","timestamp":1756354201398,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR078177"],"award-info":[{"award-number":["K23AR078177"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.amjmed.2025.04.009","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:09:39Z","timestamp":1744492179000},"page":"1304-1307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of Heparin-Induced Thrombocytopenia in Hospitalized Patients With Antiphospholipid Syndrome or Lupus With Antiphospholipid Antibodies"],"prefix":"10.1016","volume":"138","author":[{"given":"Vincent","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthini","family":"Kasturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2025.04.009_bib0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-9560-3-14","article-title":"Heparin-induced thrombocytopenia: an update","volume":"3","author":"Franchini","year":"2005","journal-title":"Thromb J"},{"key":"10.1016\/j.amjmed.2025.04.009_bib0002","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/01.smj.0000166748.90089.65","article-title":"Antiphospholipid syndrome: review","volume":"98","author":"Sammaritano","year":"2005","journal-title":"South Med J"},{"issue":"10","key":"10.1016\/j.amjmed.2025.04.009_bib0003","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.amjmed.2025.04.009_bib0004","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.amjmed.2025.04.009_bib0005","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/ard.2004.033100","article-title":"Lupus thrombocytopenia: clinical implications and prognostic significance","volume":"64","author":"Ziakas","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2025.04.009_bib0006","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.blre.2008.03.005","article-title":"The hematologic manifestations of the antiphospholipid syndrome","volume":"22","author":"Uthman","year":"2008","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.amjmed.2025.04.009_bib0007","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/ard.2007.074476","article-title":"Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome","volume":"67","author":"Alpert","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.amjmed.2025.04.009_bib0008","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0049-3848(99)00057-2","article-title":"Antiplatelet factor 4-heparin antibodies in patients with antiphospholipid antibodies","volume":"95","author":"Martinuzzo","year":"1999","journal-title":"Thrombosis Research"},{"issue":"9","key":"10.1016\/j.amjmed.2025.04.009_bib0009","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ajh.20983","article-title":"Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism","volume":"82","author":"Anderson","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.amjmed.2025.04.009_bib0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajh.21916","article-title":"Venous limb gangrene and fatal hemorrhage: adverse consequence of HIT \u201coverdiagnosis\u201d in a patient with antiphospholipid syndrome","volume":"86","author":"Smythe","year":"2011","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.amjmed.2025.04.009_bib0011","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/blood-2012-07-443051","article-title":"Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis","volume":"120","author":"Cuker","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2025.04.009_bib0012","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0961203306075562","article-title":"High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia","volume":"16","author":"Martin-Toutain","year":"2007","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.amjmed.2025.04.009_bib0013","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N","article-title":"Validation of the Sapporo criteria for antiphospholipid syndrome","volume":"43","author":"Lockshin","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.amjmed.2025.04.009_bib0014","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/jth.14587","article-title":"The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia","volume":"17","author":"Pishko","year":"2019","journal-title":"J Thromb Haemost"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325002359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325002359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T03:44:45Z","timestamp":1756352685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934325002359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0002934325002359"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.04.009","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of Heparin-Induced Thrombocytopenia in Hospitalized Patients With Antiphospholipid Syndrome or Lupus With Antiphospholipid Antibodies","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}